Global Psoriasis Drugs Market to 2022: Increasing Preference for IL-inhibitor Therapy to Conventional TNF-inhibitors
DUBLIN, Oct 26, 2018 /PRNewswire/ --
The "Psoriasis Drugs Market Analysis Report by Therapeutic Class (Interleukin-inhibitors, Tumor Necrosis Factor-inhibitors), by Treatment (Topicals, Systemic, Biologics), and Segment Forecasts, 2016 - 2022" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
The global psoriasis drugs market size is expected to be valued at USD 21.11 billion by 2022, experiencing a CAGR of 9.4% during the forecast period.
Rising disease awareness, increasing number of reimbursement strategies for biologics, and advanced diagnostic and technological tools are likely to increase the adoption of psoriasis therapeutics.
Additionally, expanding base of patients suffering from psoriasis is anticipated to fuel growth prospects. The exact causative factors for psoriasis are undetermined; however, certain genetic and environmental factors may trigger the disease onset. Most available treatments aim to decelerate disease progression by stopping hyperproliferation of keratinocyte.
Psoriasis can be classified into five types: plaque, guttate, inverse, pustular, and erythrodermic. The types vary in terms of site of disease and characterization of lesions. Erythrodermic psoriasis is the rarest and plaque psoriasis is the most prevalent type affecting patients all over the world.
Incidence rate of psoriasis has witnessed a gradual rise over the years across various geographical locations. This increase can be attributed to genetic and environmental triggers as well as lifestyle changes. Rise in prevalence rates could also be associated with declining response or developing resistance to therapies for disease control.
Further key findings from the report suggest:
-- Tumor Necrosis Factor-inhibitors dominated the market in 2016 owing to
its higher usage by healthcare practitioners and easy availability
-- TNF-inhibitors are likely to lose market shares over the forecast period
due to increasing preference for IL-inhibitor therapy to conventional
TNF-inhibitors
-- Interleukin-inhibitors is expected to register a lucrative CAGR of over
21.0% during the forecast period owing to improved safety and efficacy
profiles of Interleukin-inhibiting drugs
-- The U.S is the dominant region in the psoriasis market in terms of
revenue in 2016 due to increasing number of patients seeking treatment
and presence of well-established healthcare services
-- Japan is expected to be the fastest growing region during the same
period due to growing awareness about the disease among the populace
-- Some of the key players in this industry are AbbVie Inc.; Amgen Inc.;
Johnson & Johnson; Novartis AG; Eli Lilly & Company; AstraZeneca;
Celgene Corporation; UCB; and Merck.
Key Topics Covered:
Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Information or Data Analysis
1.2.1 Market Formulation & Validation
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
3.1 Disease Primer
3.1.1 Types:
3.1.1.1 Plaque Psoriasis
3.1.1.2 Guttate Psoriasis
3.1.1.3 Inverse Psoriasis
3.1.1.4 Pustular Psoriasis
3.1.1.5 Erythrodermic Psoriasis
3.1.2 Complications
3.2 Epidemiology by Indications
3.3 Current Prevalence for Seven Major Markets (U.S., Japan, EU5)
3.4 Current Incidence for Seven Major Markets (U.S., Japan, EU5)
3.5 Forecast Prevalence and Incidence (U.S., Japan, EU5)
Chapter 4 Global Psoriasis Drugs Market Overview
4.1 Introduction and Market Overview
4.1.1 Market by Therapeutic Class
4.1.1.1 Tumour Necrosis Factor Inhibitors
4.1.1.1.1 Adalimumab
4.1.1.1.2 Infliximab
4.1.1.1.3 Etanercept
4.1.1.2 InterleU.K.in-Inhibitors
4.1.1.2.1 Ustekinumab
4.1.1.2.2 SecU.K.inumab
4.1.1.2.3 Ixekizumab
4.1.1.2.4 Brodalumab
4.1.1.3 Vitamin D analogues
4.1.1.3.1 Calcitriol
4.1.1.3.2 Calcipotriol
4.1.1.3.3 Tacalcitol
4.1.2 Market by Treatment
4.1.2.1 Topicals
4.1.2.1.1 Over-the-counter (OTC) Topicals
4.1.2.1.2 Topical non-steroids
4.1.2.1.3 Topical Steroids
4.1.2.2 Systemic
4.1.2.2.1 Retinoid
4.1.2.2.2 Cyclosporine
4.1.2.2.3 Methotrexate
4.1.2.3 Biologics
4.1.2.3.1 Tumour necrosis factor alpha (TNF-a) inhibitors
4.1.2.3.2 InterleU.K.in 12 and 23 (IL-12/23) inhibitors
4.1.2.3.3 InterleU.K.in 17 (IL-17) inhibitor
4.1.2.3.4 T cell inhibitor
4.1.3 Market Size & Forecast
4.1.4 Sales Performance
4.1.5 Market Share Distribution
4.1.6 Market Dynamics among Leading Brands
4.2 Patent Expiry Schedule
4.3 Drivers and Challenges
4.4 Deals Landscape (2013-2017)
4.5 Pricing and Reimbursement Environment
4.6 Biosimilar Evolution
4.6.1 India
4.6.2 China
4.6.3 South Korea
4.7 SWOT Analysis
Chapter 5 Global Psoriasis Drugs Market: Pipeline Intelligence
5.1 Pipeline Landscape
5.1.1 Leading Drugs under Development
5.1.2 Key R&D Trends
5.2 Promising Drug Candidates in Pipeline
5.2.1 Late Stage Pipeline and Forecast
5.2.2 Profile of Disruptive Drugs
5.2.2.1 Risankizumab
5.2.2.2 Bimekizumab
Chapter 6 Company Profiles
Chapter 7 Market Outlook
7.1 What the Future Holds
7.2 Winners and Losers
7.3 Emerging Companies
7.4 The Road Ahead
Companies Mentioned
-- AbbVie Inc.
-- Amgen, Inc.
-- Johnson & Johnson
-- Novartis AG
-- Eli Lilly and Company
-- AstraZeneca
-- Celgene Corporation
-- UCB
-- Merck
For more information about this report visit https://www.researchandmarkets.com/research/zxdb8h/global_psoriasis?w=5
Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/global-psoriasis-drugs-market-to-2022-increasing-preference-for-il-inhibitor-therapy-to-conventional-tnf-inhibitors-300738630.html
SOURCE Research and Markets
